Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR444336 in microscopic colitis remission after budesonide
2024-519495-83-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- Oct 2025
- Modality
- Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in microscopic colitis (MC) comparing SAR444336 with Matched placebo (2 arms). Primary endpoint: Proportion of participants with sustained steroid-free clinical remission. Planned start Oct 2025; status: authorised.
02
Drugs
SAR444336
03
Conditions
microscopic colitis (MC)
Beyond the preview
Go deeper on 2024-519495-83-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519495-83-00.